STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
Stat News • 5/12/2026
Summary
Bristol Myers Squibb is partnering with China's Hengrui Pharma to advance over a dozen early-stage drugs. The deal is valued at up to $15.2 billion.
Advertisement
Lindy Score Breakdown (V4.2)
1d
Age
1
Sources
from cluster
39
Hours Since Seen
Final Score8/100
CategoryAntiLindy
StatusActive
Recency Multiplier57% (0.5^39/48)
Hero EligibleYes
Score BreakdownRisk 65
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 1 day(s) old - still early
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
Stat News • 2 days ago
Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
Stat News • 1 day ago
STAT+: STAT examines America’s deadliest drug
Stat News • 1 day ago
STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
Stat News • 2 days ago
STAT+: Drug meant to make gene therapy safer may also make it less effective
Stat News • Today
STAT+: Hims’ sales miss as telehealth competition grows
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
Stat News • Today
STAT+: In the battle of sepsis algorithms, performance alone doesn’t predict victory
Stat News • 1 day ago
STAT+: Why Marty Makary was the worst FDA commissioner in 25 years
Stat News • 1 day ago
STAT+: AI medical devices’ dirty FDA secret
Stat News • Today
